Figure 6
From: A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression
Western blot analysis for ELAVL1, HNRNPK, CDH2 and FBLN1 in tissue samples. Graph A shows that high levels of ELAVL1, HNRNPK, CDH2 and low levels FBLN1 were detected in N-GBMs compared with PsPDs in the six samples for proteomic analysis. Graph B shows the quantification of expression levels using densitometry. Graph C shows that high levels of ELAVL1, HNRNPK, CDH2 and low levels of FBLN1 were detected in GBMs (both N-GBM and R-GBM) compared with PsPDs in additional twelve samples. Graph D shows the quantification of expression levels using densitometry. * indicates the twelve additionally selected samples;** p < 0.05.